Business Description
Kyntra Bio Inc
NAICS : 541715
SIC : 2834
ISIN : US31572Q8814
Total Employee Number:
34Description
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.18 | |||||
Equity-to-Asset | -0.4 | |||||
Debt-to-Equity | -1.68 | |||||
Debt-to-EBITDA | -1.56 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -22.39 | |||||
Beneish M-Score | 60.05 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -65.1 | |||||
3-Year EBITDA Growth Rate | 45.7 | |||||
3-Year EPS without NRI Growth Rate | 45.6 | |||||
3-Year FCF Growth Rate | 71.1 | |||||
3-Year Book Growth Rate | -9.2 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -1.52 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 81.63 | |||||
9-Day RSI | 73.33 | |||||
14-Day RSI | 66.58 | |||||
3-1 Month Momentum % | -2.82 | |||||
6-1 Month Momentum % | -21.41 | |||||
12-1 Month Momentum % | 30.93 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.61 | |||||
Quick Ratio | 3.48 | |||||
Cash Ratio | 3.1 | |||||
Days Inventory | 298.04 | |||||
Days Sales Outstanding | 55.54 | |||||
Days Payable | 524.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.4 | |||||
Shareholder Yield % | 63.52 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 40.7 | |||||
Operating Margin % | -596.1 | |||||
Net Margin % | 2199.42 | |||||
EBITDA Margin % | -635.88 | |||||
FCF Margin % | -287.7 | |||||
OCF Margin % | -287.4 | |||||
ROE % | Neg. Equity | |||||
ROA % | 115.3 | |||||
ROIC % | -78.77 | |||||
3-Year ROIIC % | -215.73 | |||||
ROC (Joel Greenblatt) % | -97.09 | |||||
ROCE % | -61.69 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 1 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 0.19 | |||||
Forward PE Ratio | 2.46 | |||||
Price-to-Owner-Earnings | 5.68 | |||||
PS Ratio | 4.2 | |||||
EV-to-EBIT | -2.43 | |||||
EV-to-Forward-EBIT | -1.27 | |||||
EV-to-EBITDA | -2.45 | |||||
EV-to-Forward-EBITDA | -1.46 | |||||
EV-to-Revenue | 15.6 | |||||
EV-to-Forward-Revenue | 9.62 | |||||
EV-to-FCF | -5.42 | |||||
Price-to-GF-Value | 1.34 | |||||
Earnings Yield (Greenblatt) % | -41.15 | |||||
FCF Yield % | -68.71 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:KYNB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kyntra Bio Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 7.439 | ||
| EPS (TTM) ($) | 40.46 | ||
| Beta | 1.5186 | ||
| 3-Year Sharpe Ratio | -0.35 | ||
| 3-Year Sortino Ratio | -0.53 | ||
| Volatility % | 84.89 | ||
| 14-Day RSI | 66.58 | ||
| 14-Day ATR ($) | 0.339579 | ||
| 20-Day SMA ($) | 6.94825 | ||
| 12-1 Month Momentum % | 30.93 | ||
| 52-Week Range ($) | 5.2 - 12.6 | ||
| Shares Outstanding (Mil) | 4.05 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kyntra Bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kyntra Bio Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-10 17:00 | In 132 days | ||
| Third quarter earnings results for 2026 | 2026-11-10 | In 131 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-11 17:00 | In 41 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | In 40 days | ||
| General meeting for 2026 | 2026-06-12 08:00 | 6.76 (-3.29%) | ||
| First quarter earnings conference call for 2026 | 2026-05-11 17:00 | 6.95 (-1.42%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 6.95 (-1.42%) | ||
| 25th Annual Needham Virtual Healthcare Conference | 2026-04-13 13:30 | 7.17 (-0.69%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-16 17:00 | 6.97 (-2.04%) | ||
| Annual report for 2025 | 2026-03-16 | 6.97 (-2.04%) |
Show
Entries
Kyntra Bio Inc Frequently Asked Questions
What is Kyntra Bio Inc(KYNB)'s stock price today?
The current price of KYNB is $7.70. The 52 week high of KYNB is $12.60 and 52 week low is $5.20.
When is next earnings date of Kyntra Bio Inc(KYNB)?
The next earnings date of Kyntra Bio Inc(KYNB) is 2026-08-11 Est..
Does Kyntra Bio Inc(KYNB) pay dividends? If so, how much?
Kyntra Bio Inc(KYNB) does not pay dividend.
Guru Commentaries on NAS:KYNB
No articles.
Press Release
Articles on Kyntra Bio Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers